CAS 903512-50-5: Lucatumumab

Description:Lucatumumab, identified by the CAS number 903512-50-5, is a monoclonal antibody that primarily targets the CD37 antigen, which is expressed on the surface of certain immune cells and various hematological malignancies. This therapeutic agent is designed to modulate the immune response and has been investigated for its potential in treating conditions such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. Lucatumumab functions by binding to CD37, leading to the activation of immune effector mechanisms, including antibody-dependent cellular cytotoxicity (ADCC). Its structure is characterized by the typical Y-shaped configuration of antibodies, consisting of two heavy chains and two light chains, which facilitate its specific binding to the target antigen. The development of lucatumumab reflects the growing trend in biopharmaceuticals to utilize monoclonal antibodies for targeted therapy, aiming to improve treatment efficacy while minimizing off-target effects. As with many monoclonal antibodies, its pharmacokinetics, safety profile, and therapeutic efficacy are subjects of ongoing clinical research.

Formula:Unspecified

Synonyms:
Chir 12.12
HCD 122
Immunoglobulin G1, anti-(human CD40 (antigen)) (human monoclonal CHIR-12.12 heavy chain), disulfide with human monoclonal CHIR-12.12 light chain, dimer
Lucatumumab

Found 2 products.

Brand	Product data	Purity	Price range	Estimated delivery
	Lucatumumab REF: TM-T76729CAS: 903512-50-5	95% - 95%	167.00 €~1,499.00 €	Mon 28 Apr 25
	Lucatumumab REF: 3D-CLA1143CAS: 903512-50-5	- - -	To inquire	Thu 08 May 25